DOCK4 Knockout K-562 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the DOCK4 gene. These polyclonal knockout cells provide a loss-of-function model for investigating DOCK4-dependent pathways without introducing genetic homogeneity associated with single-cell clones. The engineered population enables researchers to study the functional consequences of DOCK4 disruption in a heterogeneous cellular context, offering a robust tool for pooled functional genomics and signaling analyses.
The parental K-562 cell line is a well-established chronic myelogenous leukemia model originally derived from a 53-year-old female patient in blast crisis. These cells harbor the BCR-ABL1 fusion oncogene and exhibit unique plasticity, capable of differentiating along erythroid, granulocytic, and monocytic lineages upon appropriate stimulation. K-562 cells are extensively utilized in hematological malignancy research, particularly for studying leukemogenesis, signal transduction, and the cytoskeletal underpinnings of tumor cell behavior.
DOCK4 functions as a guanine nucleotide exchange factor (GEF) that specifically activates the small GTPase Rac1 by catalyzing the exchange of GDP for GTP. In its active GTP-bound state, Rac1 orchestrates actin cytoskeleton remodeling through downstream effectors such as PAK kinases, the WAVE regulatory complex, and the Arp2/3 complex, ultimately promoting lamellipodia formation, cell migration, and adhesion. DOCK4 activation is tightly regulated by the adaptor protein ELMO1, which facilitates its interaction with Rac1 and links DOCK4 to upstream signals from integrins, Src family kinases, and growth factor receptors including EGFR and VEGFR. Additionally, DOCK4 modulates JNK signaling and cofilin-mediated actin dynamics, integrating multiple pathways that control cellular polarization and directional movement.
In the K-562 leukemia model, DOCK4-mediated Rac1 activation is implicated in the regulation of actin dynamics essential for cell migration and invasion. Disruption of DOCK4 is expected to impair Rac1-dependent cytoskeletal reorganization, reducing the migratory and invasive capacity of these leukemic cells. This knockout model thus provides a valuable system for dissecting the role of DOCK4-Rac1 signaling in hematological malignancies, offering insights into how aberrant cytoskeletal control contributes to disease progression and metastatic spread.
These DOCK4 knockout K-562 cells are suited for a broad range of applications, including transwell migration and Matrigel invasion assays to quantitate motility defects, as well as western blotting and Rac1 activity assays to directly monitor signaling alterations. They enable immunofluorescence analysis of F-actin organization, co-immunoprecipitation studies examining the DOCK4-ELMO1 complex, and flow cytometry-based phenotypic screening. Moreover, RNA-seq applications permit global transcriptomic profiling of DOCK4-dependent gene expression networks. For further information, please contact Ascent Research.
